NCT05806346
Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion date changed from estimate of Apr 30, 2025 to Oct 10, 2026 Show 6 more changesShow less
- Study completion date changed from estimate of Jun 30, 2025 to Oct 23, 2026
- Eligibility criteria expanded, about 11 words
- Trial completed
- Secondary endpoints: 17 to 19
- Site details revised at 3 of 3 sites
- Publications: details revised at 1 of 1 entry
- Notable Primary completion date: Aug 31, 2024 to Apr 30, 2025
- Study sites: 1 to 3
- Study completion date: Dec 31, 2024 to Jun 30, 2025
- Secondary endpoints: details revised at 3 of 17 entries
- Minor Secondary endpoints: 12 to 17v7
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Notable Phase: Phase 4 to Not applicablev5
Show 3 earlier versionsHide 3 earlier versions
- Notable Start date: May 1, 2023 to Aug 1, 2023v4
- Minor Secondary endpoints revised (12)v3
Notable Eligibility criteria expanded, about 1 wordv2 Show 5 more changesShow less
- Interventions: Tranexamic acid injection (Drug), rotational thromboelastometry (Diagnostic Test) to Placebo administration (Drug), TXA administration (Drug)
- Secondary endpoints: 4 to 12
- Study arms: 3 to 4
- Study description expanded, about 3 words
- Study title shortened, about 5 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (19)
Show 14 moreShow less
Arms and interventions
Tranexamic acid administration, regardless of the result of rotational thromboelastometry. Placebo administration, at LI60 \< 85 % or A10\< 40 mm in EXTEM of rotational thromboelastometry
Tranexamic acid administration, regardless of the result of rotational thromboelastometry. Placebo discard, at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry
Placebo administration, regardless of the result of rotational thromboelastometry. Tranexamic acid administration at LI60 \< 85 % or A10 \< 40 mm in EXTEM of rotational thromboelastometry
Placebo administration, regardless of the result of rotational thromboelastometry. Tranexamic acid discard at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry
Drugs: TXA administration, Placebo administration
Sites
3 sites in 1 country